Chemed (CHE) Releases FY18 Earnings Guidance

Chemed (NYSE:CHE) issued an update on its FY18 earnings guidance on Wednesday morning. The company provided earnings per share (EPS) guidance of $10.60-10.85 for the period, compared to the Thomson Reuters consensus estimate of $10.01.

Shares of Chemed (CHE) traded down $9.47 during trading on Thursday, reaching $244.26. The company’s stock had a trading volume of 31,601 shares, compared to its average volume of 94,766. The company has a quick ratio of 0.48, a current ratio of 0.50 and a debt-to-equity ratio of 0.15. The stock has a market cap of $3,981.60, a PE ratio of 56.38 and a beta of 1.13. Chemed has a 1-year low of $170.69 and a 1-year high of $275.83.

Chemed (NYSE:CHE) last announced its quarterly earnings results on Wednesday, February 14th. The company reported $2.32 EPS for the quarter, topping the Zacks’ consensus estimate of $2.27 by $0.05. The business had revenue of $428.35 million for the quarter, compared to analysts’ expectations of $423.83 million. Chemed had a return on equity of 27.69% and a net margin of 4.62%. The business’s quarterly revenue was up 6.2% on a year-over-year basis. During the same period in the previous year, the firm earned $2.10 EPS.

A number of equities research analysts have recently weighed in on CHE shares. TheStreet upgraded Chemed from a c+ rating to an a- rating in a research report on Friday, October 27th. Zacks Investment Research upgraded Chemed from a hold rating to a buy rating and set a $251.00 price objective on the stock in a research report on Thursday, November 2nd. KeyCorp reiterated a hold rating on shares of Chemed in a research report on Friday, October 27th. ValuEngine lowered Chemed from a buy rating to a hold rating in a research report on Friday, December 1st. Finally, Oppenheimer lifted their price objective on Chemed from $220.00 to $225.00 and gave the stock an outperform rating in a research report on Friday, October 27th. Four analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. The company currently has an average rating of Hold and a consensus target price of $236.00.

In other Chemed news, VP Naomi C. Dallob sold 950 shares of the business’s stock in a transaction on Monday, November 27th. The stock was sold at an average price of $240.38, for a total value of $228,361.00. Following the sale, the vice president now directly owns 9,747 shares of the company’s stock, valued at $2,342,983.86. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Spencer S. Lee sold 1,000 shares of the business’s stock in a transaction on Wednesday, November 22nd. The stock was sold at an average price of $238.24, for a total value of $238,240.00. Following the completion of the sale, the insider now directly owns 34,809 shares in the company, valued at $8,292,896.16. The disclosure for this sale can be found here. Insiders have sold 13,950 shares of company stock worth $3,370,681 over the last 90 days. 4.90% of the stock is currently owned by corporate insiders.

WARNING: This story was published by Markets Daily and is owned by of Markets Daily. If you are reading this story on another publication, it was stolen and republished in violation of US and international copyright & trademark legislation. The correct version of this story can be read at https://www.themarketsdaily.com/2018/02/15/chemed-che-releases-fy18-earnings-guidance.html.

Chemed Company Profile

Chemed Corporation purchases, operates and divests subsidiaries engaged in various business activities. The Company operates through two segments: the VITAS segment (VITAS) and the Roto-Rooter segment (Roto-Rooter). The Company’s VITAS provides hospice and palliative care services to its patients through a network of physicians, registered nurses, home health aides, social workers, clergy and volunteers.

Receive News & Ratings for Chemed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemed and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply